BRCA1-A good predictive marker of drug sensitivity in breast cancer treatment?

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1766, Issue 2, 2006, Pages 205-216

  Mullan, Paul B ^a   Gorski, Julia J ^a   Harkin, D Paul ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

BRCA1; Chemotherapy; Predictive marker; Response

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; NAVELBINE; NOCODAZOLE; PACLITAXEL; PREDNISOLONE; TAXANE DERIVATIVE; VINBLASTINE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; TUMOR MARKER;

ADJUVANT THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DNA DAMAGE; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; HEREDITY; HUMAN; MICROTUBULE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SURVIVAL RATE; BREAST TUMOR; DNA REPAIR; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; BREAST NEOPLASMS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICROTUBULES; TUMOR MARKERS, BIOLOGICAL;

EID: 33847304077     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2006.07.001     Document Type: Review

References (98)

1. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (1994) 66-71
2. King M.C., Marks J.H., and Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (2003) 643-646
3. Futreal P.A., Liu Q., Shattuck-Eidens D., Cochran C., Harshman K., Tavtigian S., et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266 (1994) 120-122
4. Katagiri T., Emi M., Ito I., Kobayashi K., Yoshimoto M., Iwase T., et al. Mutations in the BRCA1 gene in Japanese breast cancer patients. Human Mutat. 7 (1996) 334-339
5. Janatova M., Zikan M., Dundr P., Matous B., and Pohlreich P. Somatic mutations in the BRCA1 gene in sporadic breast tumors. Human Mutat. 25 (2005) 319
6. Catteau A., Harris W.H., Xu C.F., and Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18 (1999) 1957-1965
7. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol. 4 (2003) 351-358
8. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92 (2000) 564-569
9. Kennedy R.D., Quinn J.E., Johnston P.G., and Harkin D.P. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 360 (2002) 1007-1014
10. Quinn J.E., Kennedy R.D., Mullan P.B., Gilmore P.M., Carty M., Johnston P.G., et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 63 (2003) 6221-6228
11. Bhattacharyya A., Ear U.S., Koller B.H., Weichselbaum R.R., and Bishop D.K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275 (2000) 23899-23903
12. Moynahan M.E., Cui T.Y., and Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 61 (2001) 4842-4850
13. Fedier A., Steiner R.A., Schwarz V.A., Lenherr L., Haller U., and Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 22 (2003) 1169-1173
14. Lafarge S., Sylvain V., Ferrara M., and Bignon Y.J. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20 (2001) 6597-6606
15. Husain A., He G., Venkatraman E.S., and Spriggs D.R. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res. 58 (1998) 1120-1123
16. Sylvain V., Lafarge S., and Bignon Y.J. Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int. J. Oncol. 20 (2002) 845-853
17. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
18. Scully R., Ganesan S., Vlasakova K., Chen J., Socolovsky M., and Livingston D.M. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol. Cell. Dec. 4 6 (1999) 1093-1099
19. Ruffner H., Joazeiro C.A., Hemmati D., Hunter T., and Verma I.M. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 5134-5139
20. Hedenfalk I., Duggan D., Chen Y., Radmacher M., Bittner M., Simon R., et al. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344 (2001) 539-548
21. Chappuis P.O., Goffin J., Wong N., Perret C., Ghadirian P., Tonin P.N., et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J. Med. Genet. 39 (2002) 608-610
22. Kirova Y.M., Stoppa-Lyonnet D., Savignoni A., Sigal-Zafrani B., Fabre N., and Fourquet A. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur. J. Cancer 41 (2005) 2304-2311
23. Goffin J.R., Chappuis P.O., Begin L.R., Wong N., Brunet J.S., Hamel N., et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 97 (2003) 527-536
24. Delaloge S.P.P., Kloos I., et al. BRCA1-linked breast cancer (BC) is highly more chemosensitive than its BRCA2-linked or sporadic counterparts. Program and abstracts of the 27th Congress of the European Society for Medical Oncology (2002) Abstract 120
25. Cass I., Baldwin R.L., Varkey T., Moslehi R., Narod S.A., and Karlan B.Y. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97 (2003) 2187-2195
26. Majdak E.J., Debniak J., Milczek T., Cornelisse C.J., Devilee P., Emerich J., et al. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 104 (2005) 1004-1012
27. Yang Q.S.T., Mori I., et al. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer 92 (2001) 54-60
28. Wang C., Horiuchi A., Imai T., Ohira S., Itoh K., Nikaido T., et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J. Pathol. 202 (2004) 215-223
29. Teodoridis J.M., Hall J., Marsh S., Kannall H.D., Smyth C., Curto J., et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 65 (2005) 8961-8967
30. Taron M., Rosell R., Felip E., Mendez P., Souglakos J., Ronco M.S., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet. 13 (2004) 2443-2449
31. Seynaeve C., and Brekelmans C.T. Tailoring breast cancer therapy to genetic status. Lancet 365 (2005) 1672-1673
32. Pierce L.J., Levin A.M., Rebbeck T.R., Ben-David M.A., Friedman E., Solin L.J., et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J. Clin. Oncol. 24 (2006) 2437-2443
33. Gasparini G., Caffo O., Barni S., Frontini L., Testolin A., Guglielmi R.B., et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J. Clin. Oncol. 12 (1994) 2094-2101
34. Wang Q.E., Zhu Q., Wani G., Chen J., and Wani A.A. UV radiation-induced XPC translocation within chromatin is mediated by damaged-DNA binding protein, DDB2. Carcinogenesis 25 (2004) 1033-1043
35. Bishop J.F., Dewar J., Toner G.C., Smith J., Tattersall M.H., Olver I.N., et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J. Clin. Oncol. 17 (1999) 2355-2364
36. Piccart M.J., Du Bois A., Gore M.E., Neijt J.P., Pecorelli S., and Pujade-Lauraine E. A new standard of care for treatment of ovarian cancer. Eur. J. Cancer 36 (2000) 10-12
37. Basu A., You S.A., and Haldar S. Regulation of Bcl2 phosphorylation by stress response kinase pathway. Int. J. Oncol. 16 (2000) 497-500
38. Haldar S., Basu A., and Croce C.M. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res. 58 (1998) 1609-1615
39. Jones R.K., Searle R.F., Stewart J.A., Turner S., and Bulmer J.N. Apoptosis, bcl-2 expression, and proliferative activity in human endometrial stroma and endometrial granulated lymphocytes. Biol. Reprod. 58 (1998) 995-1002
40. Mullan P.B., Quinn J.E., Gilmore P.M., McWilliams S., Andrews H., Gervin C., et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 20 (2001) 6123-6131
41. Tassone P., Tagliaferri P., Perricelli A., Blotta S., Quaresima B., Martelli M.L., et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br. J. Cancer 88 (2003) 1285-1291
42. Wang R.H., Yu H., and Deng C.X. A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17108-17113
43. Xu X., Weaver Z., Linke S.P., Li C., Gotay J., Wang X.W., et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3 (1999) 389-395
44. Nowak A.K., Wilcken N.R., Stockler M.R., Hamilton A., and Ghersi D. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol. 5 (2004) 372-380
45. Gebbia V., Blasi L., Borsellino N., Caruso M., Leonardi V., Agostara B., et al. Paclitaxel and epidoxorubicin or doxorubicin versus cyclophosphamide and epidoxorubicin as first-line chemotherapy for metastatic breast carcinoma: a randomised phase II study. Anticancer Res. 23 (2003) 765-771
46. Smith I.C., Heys S.D., Hutcheon A.W., Miller I.D., Payne S., Gilbert F.J., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J. Clin. Oncol. 20 (2002) 1456-1466
47. Henderson I.C., Berry D.A., Demetri G.D., Cirrincione C.T., Goldstein L.J., Martino S., et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 21 (2003) 976-983
48. Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., and Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 14 (2000) 927-939
49. Karran P. DNA double strand break repair in mammalian cells. Curr. Opin. Genet. Dev. 10 (2000) 144-150
50. Zhong Q., Chen C.F., Chen P.L., and Lee W.H. BRCA1 facilitates microhomology-mediated end joining of DNA double strand breaks. J. Biol. Chem. 277 (2002) 28641-28647
51. Zhang J., Willers H., Feng Z., Ghosh J.C., Kim S., Weaver D.T., et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol. Cell. Biol. 24 (2004) 708-718
52. Kim S.S., Cao L., Li C., Xu X., Huber L.J., Chodosh L.A., et al. Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1. Mol. Cell. Biol. 24 (2004) 9498-9507
53. Zhuang J., Zhang J., Willers H., Wang H., Chung J.H., van Gent D.C., et al. Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining. Cancer Res. 66 (2006) 1401-1408
54. Peng M., Litman R., Jin Z., Fong G., and Cantor S.B. BACH1 is a DNA repair protein supporting BRCA1 damage response. Oncogene 25 (2006) 2245-2253
55. Yu X., Chini C.C., He M., Mer G., and Chen J. The BRCT domain is a phospho-protein binding domain. Science 302 (2003) 639-642
56. Bridge W.L., Vandenberg C.J., Franklin R.J., and Hiom K. The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair. Nat. Genet. 37 (2005) 953-957
57. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn M.S., Timmers C., Hejna J., et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7 (2001) 249-262
58. Aglipay J.A., Martin S.A., Tawara H., Lee S.W., and Ouchi T. ATM activation by ionizing radiation requires BRCA1-associated BAAT1. J. Biol. Chem. 281 (2006) 9710-9718
59. Foray N., Marot D., Gabriel A., Randrianarison V., Carr A.M., Perricaudet M., et al. A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein. EMBO J. 22 (2003) 2860-2871
60. Zdraveski Z.Z., Mello J.A., Marinus M.G., and Essigmann J.M. Multiple pathways of recombination define cellular responses to cisplatin. Chem. Biol. 7 (2000) 39-50
61. Le Page F., Randrianarison V., Marot D., Cabannes J., Perricaudet M., Feunteun J., et al. BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res. 60 (2000) 5548-5552
62. Anderson S.F., Schlegel B.P., Nakajima T., Wolpin E.S., and Parvin J.D. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat. Genet. 19 (1998) 254-256
63. Kleiman F.E., Wu-Baer F., Fonseca D., Kaneko S., Baer R., and Manley J.L. BRCA1/BARD1 inhibition of mRNA 3′ processing involves targeted degradation of RNA polymerase II. Genes Dev. 19 (2005) 1227-1237
64. Lee K.B., Wang D., Lippard S.J., and Sharp P.A. Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase II in vitro. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 4239-4244
65. Hartman A.R., and Ford J.M. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat. Genet. 32 (2002) 180-184
66. Yarden R.I., and Brody L.C. BRCA1 interacts with components of the histone deacetylase complex. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4983-4988
67. Bochar D.A., Wang L., Beniya H., Kinev A., Xue Y., Lane W.S., et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 102 (2000) 257-265
68. Ouchi T., Monteiro A.N., August A., Aaronson S.A., and Hanafusa H. BRCA1 regulates p53-dependent gene expression. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 2302-2306
69. Li H., Lee T.H., and Avraham H. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J. Biol. Chem. 277 (2002) 20965-20973
70. Houvras Y., Benezra M., Zhang H., Manfredi J.J., Weber B.L., and Licht J.D. BRCA1 physically and functionally interacts with ATF1. J. Biol. Chem. 275 (2000) 36230-36237
71. Ouchi T., Lee S.W., Ouchi M., Aaronson S.A., and Horvath C.M. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5208-5213
72. Aprelikova O., Kuthiala A., Bessho M., Ethier S., and Liu E.T. BRCA1 protein level is not affected by peptide growth factors in MCF10A cell line. Oncogene 13 (1996) 2487-2491
73. Wang X., Gorospe M., and Holbrook N.J. gadd45 is not required for activation of c-Jun N-terminal kinase or p38 during acute stress. J. Biol. Chem. 274 (1999) 29599-29602
74. Hollander M.C., Sheikh M.S., Bulavin D.V., Lundgren K., Augeri-Henmueller L., Shehee R., et al. Genomic instability in Gadd45a-deficient mice. Nat. Genet. 23 (1999) 176-184
75. MacLachlan T.K., Somasundaram K., Sgagias M., Shifman Y., Muschel R.J., Cowan K.H., et al. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J. Biol. Chem. 275 (2000) 2777-2785
76. Yarden R.I., Pardo-Reoyo S., Sgagias M., Cowan K.H., and Brody L.C. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat. Genet. 30 (2002) 285-289
77. Aprelikova O.N., Fang B.S., Meissner E.G., Cotter S., Campbell M., Kuthiala A., et al. BRCA1-associated growth arrest is RB-dependent. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11866-11871
78. Ree A.H., Bratland A., Nome R.V., Stokke T., and Fodstad O. Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1. Oncogene 22 (2003) 8952-8955
79. Xu B., O'Donnell A.H., Kim S.T., and Kastan M.B. Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res. 62 (2002) 4588-4591
80. Zhang H., Somasundaram K., Peng Y., Tian H., Bi D., Weber B.L., et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16 (1998) 1713-1721
81. Rodriguez M., Yu X., Chen J., and Songyang Z. Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains. J. Biol. Chem. 278 (2003) 52914-52918
82. MacLachlan T.K., Takimoto R., and El-Deiry W.S. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol. Cell. Biol. 22 (2002) 4280-4292
83. Ongusaha P.P., Ouchi T., Kim K.T., Nytko E., Kwak J.C., Duda R.B., et al. BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest. Oncogene 22 (2003) 3749-3758
84. MacLachlan T.K., Dash B.C., Dicker D.T., and El-Deiry W.S. Repression of BRCA1 through a feedback loop involving p53. J. Biol. Chem. 275 (2000) 31869-31875
85. Somasundaram K., MacLachlan T.K., Burns T.F., Sgagias M., Cowan K.H., Weber B.L., et al. BRCA1 signals ARF-dependent stabilization and coactivation of p53. Oncogene 18 (1999) 6605-6614
86. Arizti P., Fang L., Park I., Yin Y., Solomon E., Ouchi T., et al. Tumor suppressor p53 is required to modulate BRCA1 expression. Mol. Cell. Biol. 20 (2000) 7450-7459
87. Halazonetis T.D., and Kandil A.N. Determination of the c-MYC DNA-binding site. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 6162-6166
88. Wang Q., Zhang H., Kajino K., and Greene M.I. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene 17 (1998) 1939-1948
89. Kennedy R.D., Gorski J.J., Quinn J.E., Stewart G.E., James C.R., Moore S., et al. BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res. 65 (2005) 10265-10272
90. Harkin D.P., Bean J.M., Miklos D., Song Y.H., Truong V.B., Englert C., et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 97 (1999) 575-586
91. Gilmore P.M., McCabe N., Quinn J.E., Kennedy R.D., Gorski J.J., Andrews H.N., et al. BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3. Cancer Res. 64 (2004) 4148-4154
92. Yujiri T., Fanger G.R., Garrington T.P., Schlesinger T.K., Gibson S., and Johnson G.L. MEK kinase 1 (MEKK1) transduces c-Jun NH2-terminal kinase activation in response to changes in the microtubule cytoskeleton. J. Biol. Chem. 274 (1999) 12605-12610
93. Hsu L.C., and White R.L. BRCA1 is associated with the centrosome during mitosis. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 12983-12988
94. Hsu L.C., Doan T.P., and White R.L. Identification of a gamma-tubulin-binding domain in BRCA1. Cancer Res. 61 (2001) 7713-7718
95. Deng C.X. Roles of BRCA1 in centrosome duplication. Oncogene 21 (2002) 6222-6227
96. Sankaran S., Starita L.M., Groen A.C., Ko M.J., and Parvin J.D. Centrosomal microtubule nucleation activity is inhibited by BRCA1-dependent ubiquitination. Mol. Cell. Biol. 25 (2005) 8656-8668
97. Starita L.M., Machida Y., Sankaran S., Elias J.E., Griffin K., Schlegel B.P., et al. BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol. Cell. Biol. 24 (2004) 8457-8466
98. Narod S.A., Goldgar D., Cannon-Albright L., Weber B., Moslehi R., Ives E., et al. Risk modifiers in carriers of BRCA1 mutations. Int. J. Cancer 64 (1995) 394-398